TDOC
Teladoc Health, Inc. (TDOC) ESG Analysis Analysis (2026)
Environmental
Teladoc’s digital-care model lowers direct facility energy and waste intensity versus hospital-heavy peers, but the environmental footprint remains less differentiated than pure software healthcare platforms.
R&D intensity of 10.8% of revenue supports a relatively asset-light operating model, yet peer advantages are limited because most telehealth competitors also operate with low physical infrastructure.
The absence of disclosed capital-intensive manufacturing or logistics exposure reduces Scope 1 and 2 complexity versus traditional healthcare services peers, though third-party cloud and data-center emissions still matter.
Environmental disclosure appears narrower than best-in-class healthcare technology peers, which can leave climate and resource-management oversight less transparent to investors and regulators.
Social
Teladoc’s core service expands access to care and can improve patient convenience versus in-person-only providers, but peer differentiation is constrained because telehealth is now widely adopted.
The platform’s social value is supported by broad digital reach, yet outcomes depend on clinical quality, making peer comparison sensitive to care coordination and patient experience standards.
Stock-based compensation at 1.9% of revenue suggests lower dilution pressure, but it is not a major social differentiator relative to other growth-oriented healthcare technology peers.
As a virtual-care provider, Teladoc faces elevated privacy, trust, and service-continuity expectations, and peers with stronger brand and utilization stability may be better positioned socially.
Governance
Debt-to-equity of 0.79 and current ratio of 0.83 indicate a tighter liquidity and leverage profile, which weakens governance flexibility versus better-capitalized healthcare technology peers.
High leverage and sub-1.0 current ratio can constrain board discretion and increase refinancing sensitivity, making capital-allocation oversight more important than at peers with cleaner balance sheets.
R&D spending at 10.8% of revenue shows continued product investment, but governance quality is only moderate because the metric does not by itself demonstrate disciplined returns.
Stock-based compensation at 1.9% of revenue is manageable, yet governance remains below stronger peers if equity incentives are not clearly tied to durable operating and compliance outcomes.
Overall Score
Teladoc’s ESG profile remains broadly middle-tier versus peers, with access-to-care benefits still offset by a tighter liquidity/leverage profile that weakens governance.
Score Driver: Leverage And Liquidity Constraints Remain The Main Drag On Governance, While The Social Benefit Of Digital Care Is Unchanged.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Teladoc Health, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

